Magnetic Resonance Study A Step Forward in Breast Cancer Detection

By Petrina Smith
Tuesday, 03 March, 2015


A new magnetic resonance spectroscopy (MRS) technique has been developed that will potentially reduce the need for women at risk of breast cancer to undergo preventive mastectomies.
Published in the US journal Radiology*, the non-invasive Magnetic resonance study detected a series of biochemical changes in breast tissue which could provide early warning signs and improve ongoing risk management for women with BRCA gene abnormalities.
Mutations with BRCA1 and BRCA2 bring a 50 per cent risk of developing breast cancer before the age of 50, and many carriers currently opt to have mastectomies to avoid getting cancer later in life.
Using a technique known as localised correlated spectroscopy (L-COSY), researchers from the University of Newcastle and Brigham and Women’s Hospital in Boston identified chemical disparities associated with the pre-invasive cancer state – a very early stage of disease development.
“These changes appear to represent a series of early warning signs that may allow women to make informed decisions as to when and if they have a prophylactic mastectomy,” said lead author Professor Carolyn Mountford, CEO and Director of Research at the Translational Research Institute (TRI) in Queensland and conjoint professor with the University of Newcastle.
“It took a multidisciplinary team, including an MR physicist, chemists, surgeons and radiologists to be sure that what we were seeing wasn’t apparent from conventional contrast-enhanced imaging.”
The researchers performed L-COSY on 23 women carrying BRCA mutations and compared the results with those from 10 healthy controls who had no family history of breast cancer.
While no abnormality was recorded by standard contrast-enhanced MRI scans and ultrasound, L- COSY identified statistically significant biochemical changes in women with BRCA1 and BRCA2 gene mutations compared to the controls.
Study co-author Dr David Clark, from the Breast and Endocrine Centre in Gateshead (NSW), believes the protocol may help guide treatment decisions and bring added reassurance for BRCA- positive women.
“We think there are three stages of pre-cancer progression in the breast tissue,” he said. “Women at Stage 1 could monitor their breasts with follow-up spectroscopy every six months.
“Approximately half the women who have BRCA mutations may not develop breast cancer at all, and certainly not before they turn 50, so we can advise a significant number of them that, yes, they may need a mastectomy one day ... but not yet.”
Dr Saadallah Ramadan, a physical chemist from the University of Newcastle and HMRI researcher, specifically programmed the MR scanners to suit the innovative L-COSY protocol as the software is not commercially available.
“It’s the first time in the world it has been used for BRCA and the results were very assuring,” Dr Ramadan said. “Our error margin was small enough to suggest the test can be repeatable on a larger scale.”
The researchers now aim to expand the trial and will continue to monitor women in the original study group to learn more about the biochemical changes and what they represent.
The study was conducted at the University of Newcastle’s Centre for MR in Health, using a state- of-the-art Siemens Magnetom Prisma 3T scanner, and the Calvary Mater Newcastle in conjunction with the HMRI Cancer Research Program

Related Articles

New Precision Care Clinic at NSW's Prince of Wales Hospital

The clinic will provide personalised and tailored care for cancer and hopes to facilitate rapid...

Long COVID no different to other post-viral syndromes?

Latest research led by Queensland's Chief Health Officer Dr John Gerrard suggests long COVID...

Open water swimming: identifying and managing SIPE

SIPE occurs when excess fluid accumulates in the lungs, causing acute shortness of breath during...


  • All content Copyright © 2024 Westwick-Farrow Pty Ltd